[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inborn-errors-of-immunity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inborn-errors-of-immunity":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100575535","immunodysregulation-as-an-expression-of-underlying-inborn-errors-of-immunity-implementation-of-diagnostics-and-management-of-pediatric-and-adult-patients-with-immune-system-disorders-100575535",false,"NCT06773546","Immunodysregulation As an Expression of Underlying Inborn Errors of Immunity: Implementation of Diagnostics and Management of Pediatric and Adult Patients with Immune System Disorders","Inclusion Criteria:\n\n* patients with confirmed or suspected Inborn Errors of Immunity;\n* age \\\u003C 50 years at onset of clinical features suspected for Inborn Errors of Immunity;\n* obtaining informed consent from patients or parents\u002Flegal guardian of pediatric patients.\n\nExclusion Criteria:\n\n• patients in whom infectious susceptibility and immunodysregulation can only be attributed to known non-immunological causes: acquired immunodeficiency secondary to chronic infections (HIV), and acquired immunodeficiency secondary to immunosuppressive treatment.","ALL","50 Years",{"count":18,"type":19},400,"ESTIMATED","OBSERVATIONAL","This is an observational, retro-prospective, moncentric study focused on Inborn Errors of Immunity, an heterogeneous group of inherited diseases due to defects in the differentiation and\u002For function of the immune system. The primary aim of this study is to obtain a clinical-immunological, functional and molecular characterisation of paediatric and adult patients with confirmed or suspected Inborn Errors of Immunity, particularly of patients with manifestations of immunedysregulation, focusing on clinical course, immunophenotypic laboratory and functional abnormalities, genetic background.",[23],"Inborn Errors of Immunity",[25],"Inborn errors of immunity","RECRUITING","2025-01-13",{"date":29,"type":30},"2025-01-14","ACTUAL",{"date":32,"type":30},"2023-09-15",{"date":34,"type":19},"2026-12-31",{"name":36,"class":37},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":38},"100531409","phase-2-ptcy-and-and-ruxolitinib-for-gvhd-prophylaxis-after-hsct-with-thymoglobulin-in-conditioning-regimen-in-patients-with-inborn-errors-of-immunity-100531409","NCT06199427","PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity","Safety and Efficacy of Cyclophosphamide and Ruxolitinib for Graft-versus-host-disease Prophylaxis After Hematopoietic Stem Cell Transplantation With Thymoglobulin Serotherapy in Conditioning Regimen in Patients With Inborn Errors of Immunity","Inclusion Criteria:\n\n1. Patients aged ≥ 0 months and \\\u003C 21 years\n2. Patients diagnosed with NBS eligible for an allogeneic HSCT\n3. Signed written informed consent signed by a parent or legal guardian\n\nExclusion Criteria:\n\nConcomitant severe somatic disease associated with an additional risk of severe complications","0 Months","21 Years",{"count":49,"type":19},100,"INTERVENTIONAL",[52],"PHASE2","The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)",[23],"2023-12-28",{"date":57,"type":30},"2024-01-10",{"date":59,"type":30},"2023-11-21",{"date":61,"type":19},"2027-12-31",{"name":63,"class":37},"Federal Research Institute of Pediatric Hematology, Oncology and Immunology"]